Last Updated: May 21, 2024
cll-treatmentoption.com has 4 NS records, 2 A records, 0 AAAA records, 0 MX records, and 0 TXT records. Name servers for cll-treatmentoption.com are ns1.bms.com, ns4.bms.com, ns2.bms.com, ns3.bms.com. A records for cll-treatmentoption.com are , 165.89.235.20. The domain's primary website is hosted on a Microsoft-IIS/10.0 web server at 165.89.235.20 in United States. The website's description is: "breyanzi® (lisocabtagene maraleucel) car t cell therapy treatment is used to treat adult patients with relapsed/refractory large b-cell lymphoma (lbcl) and chronic lymphocytic leukemia (cll). please see full prescribing information, including boxed warnings and medication guide."
Search DigitalStakeout Footprint to find another asset.
No DNS A records
No DNS AAAA records
No DNS MX records
ns1.bms.com
ns4.bms.com
ns2.bms.com
ns3.bms.com
No DNS TXT records
No subdomains found. Please check back at a later time.
Microsoft-IIS/10.0
165.89.235.20
United States
og:title: breyanzi® (lisocabtagene maraleucel) car t cell therapy treatment
og:site_name: breyanzi® (lisocabtagene maraleucel) patient site
og:url: https://www.breyanzi.com/
og:description: breyanzi® (lisocabtagene maraleucel) car t cell therapy treatment is used to treat adult patients with relapsed/refractory large b-cell lymphoma (lbcl) and chronic lymphocytic leukemia (cll). please see full prescribing information, including boxed warnings and medication guide.
og:image: https://www.breyanzi.com/assets/commercial/us/breyanzidtc/en/images/breyanzi_rgb-logo.png
No certificate log entry found for cll-treatmentoption.com. Please check back at a later time.